terazosin / Generic mfg. - LARVOL DELTA

ATF3 Deficiency Exacerbates Ageing-Induced Atherosclerosis and Clinical Intervention Strategy. (PubMed, Adv Sci (Weinh)) - "Terazosin (TZ) diminishes the interaction between YTH N6-methyladenosine RNA binding protein F2 (YTHDF2) and Atf3 mRNA, helping to preserve Atf3 mRNA stability...ATF3 protects against VSMC senescence and AS by orchestrating autophagy via a novel ATF3-ATG7 amplification loop. Repurposing TZ to stabilize ATF3 offers a translatable approach to combat ageing-driven cardiovascular disease."

Journal • Atherosclerosis • Cardiovascular • ATF3 • ATG7 • YTHDF2

Do transdermal administration of α1 and α2 adrenergic receptor antagonists modulate sweating in exercising young females in the heat? (PubMed, Skin Pharmacol Physiol) - "Sweat rates (ventilated capsule technique) on both forearms were assessed following pre-treatment with terazosin (α1-adrenergic receptor antagonist), rauwolscine (α2-antagonist), or control (NaCl) using transdermal iontophoresis procedure. Rauwolscine effectively abolished clonidine-induced cutaneous vasoconstriction in a follow-up study, verifying successful transdermal delivery. Conclusion The α₁- and α₂-adrenergic receptors do not alter sweating during moderate-intensity exercise in males and females, at least among individuals with relatively low sweat production."

Journal

Tetrahydrofuran-containing Pharmaceuticals: Targets, Pharmacological Activities, and Their SAR Studies. (PubMed, ChemMedChem) - "The US Food and Drug Administration (FDA) has approved a total of 13 drugs for a range of clinical diseases， such as Terazosin and Darunavir. These drugs exhibit superior pharmacological effects in multiple therapeutic fields. This review offers an extensive overview of FDA-approved drugs containing the tetrahydrofuran nucleus, emphasizing their pharmacological activities and structure-activity relationships."

Journal

New Lead Schiff Bases Predominantly Mediate Vasorelaxant Activity Through α1 Receptor Blocking Activity. (PubMed, Biomolecules) - "Terazosin served as a standard α1 receptor blocker...Additive effects of SB1 and SB2 were seen in the presence of verapamil (p < 0.0001). Docking analysis revealed that the compounds can properly bind to the target receptor Gq 1D (P25100). Findings show that both Schiff base SB1 and SB2 produce significant (p < 0.05) vasorelaxation via the α1 receptor blocking mechanism."

Journal • Gastrointestinal Disorder • Pain

Managing Page Kidney in a Patient With Underlying Renal Cell Carcinoma: A Case Report (ATS 2025) - "Blood pressure stabilized with adjusted medication, and he was discharged on five anti-hypertensives (Amlodipine, Hydralazine, Losartan, Metoprolol and Terazosin). If medical management fails, surgical intervention such as capsulotomy, hematoma evacuation, or nephrectomy may be necessary, particularly for large or expanding hematomas. Optimal outcomes are achieved through multidisciplinary management involving Urology, Nephrology, and Interventional Radiology."

Case report • Clinical • Acute Kidney Injury • Autism Spectrum Disorder • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Genetic Disorders • Genito-urinary Cancer • Hematological Disorders • Hypertension • Nephrology • Oncology • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Urology

TRAM: Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms (clinicaltrials.gov) - P3 | N=150 | Not yet recruiting | Sponsor: Penang Hospital, Malaysia

New P3 trial

Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models. (PubMed, Antioxidants (Basel)) - "We demonstrated that some of the medications, used in combination, can exert an additive neuroprotective effect in preclinical models of PD that is superior to that of each of the compounds individually. This project can lead to the development of the first treatment for PD that can slow or prevent its progression."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • NEFH

Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform. (PubMed, Mov Disord) - "Drug selection in DMT PD MAMS trials requires consideration of scientific and practical issues. We present a robust system that can inform similar initiatives."

Journal • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease

Glycolysis-enhancing α1-adrenergic antagonists are neuroprotective in Alzheimer's disease. (PubMed, bioRxiv) - "Terazosin (TZ) is an α 1 -adrenergic receptor antagonist that enhances glycolysis by activating the enzyme phosphoglycerate kinase 1 (PGK1). Finally, in a large human administrative dataset, we found that patients taking TZ or related glycolysis-enhancing drugs had a lower hazard of being diagnosed with AD compared to those taking tamsulosin or 5-alpha reductase inhibitors. These data further implicate metabolism in neurodegenerative diseases and suggest that glycolysis-enhancing drugs may be neuroprotective in AD."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Movement Disorders • Parkinson's Disease • Solid Tumor • PGK1

Phosphoglycerate kinase 1 as a therapeutic target in neurological disease. (PubMed, Trends Mol Med) - "This review examines recent evidence that suggests increasing PGK1 activity may be beneficial in multiple neurological conditions and discusses the current challenges surrounding the development of PGK1-focused therapies. PGK1 has considerable therapeutic potential, but novel PGK1 activators are needed to maximize the benefit for patients."

Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders • Genetic Disorders • Movement Disorders • Parkinson's Disease • Rare Diseases • PGK1

Extended multidimensional design space studies: Comparing volatile and non-volatile buffer systems in UPLC. (PubMed, J Chromatogr A) - "To explore this, we utilized an Analytical Quality by Design (AQbD) modeling approach with DryLab to construct and compare three-dimensional (tG-T-pH) separation models for terazosin and selected impurities across a pH range of 6.0-8.0. These Design Space (DS) models provided a comprehensive understanding of the dynamic changes occurring within each separation system. Notably, our findings revealed not only equivalent separation performance, as indicated by overlapping Method Operable Design Regions (MODRs), but also critical insights into buffer-specific differences in the selectivity of HPLC-separations."

Journal

Risk assessment of the top 50 drugs associated with drug-induced orthostatic hypotension: a disproportionality analysis of the FAERS and JADER databases. (PubMed, Sci Rep) - "The three drugs with the highest ROR risk signals were terazosin [ROR (95% CI): 153.96 (124.57-190.28)], rasagiline [ROR (95% CI): 37.46 (29.99-46.78)], and doxazosin [ROR (95% CI): 37.06 (31.32-43.86)]. This study employed the FAERS database to identify 33 drugs that may be potentially linked to orthostatic hypotension. Medical workers should remain vigilant regarding the risk of these drugs causing orthostatic hypotension."

Journal • Cardiovascular • Hypertension • Hypotension

Posterior Reversible Encephalopathy Syndrome as a Presenting Finding of Multiple Endocrine Neoplasia type 2A Syndrome: A Case Report (AAN 2025) - "He was treated with terazosin and antihypertensives, resulting in rapid symptom improvement...This case highlights that PRES can occur secondary to a pheochromocytoma crisis, as with MEN2A syndrome. Clinicians should consider pheochromocytoma and related genetic conditions in young patients with PRES from severe, undifferentiated hypertension."

Case report • Clinical • Cardiovascular • CNS Disorders • Endocrine Cancer • Hypertension • Movement Disorders • Multiple Sclerosis • Neuroendocrine Tumor • Oncology • Pain • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma

Evaluation Of Additive Neuroprotective Effect of Combination Therapy For Parkinson's Disease Using in Vitro Models (AAN 2025) - "Therefore, combinations of medications targeting different disease mechanisms simultaneously may show additive or synergistic efficacy in slowing Parkinson's Disease progression.Design/We evaluated 44 combinations of the nine medications and supplements (sodium phenylbutyrate, terazosin, exenatide, ambroxol, deferiprone, coenzyme-Q10, creatine, dasatinib and tauroursodeoxycholic acid), chosen for their effect on different targets, that had shown neuroprotective effects in preclinical models of Parkinson's Disease. We demonstrated that some of the medications and food supplements, used in combination, can exert an additive neuroprotective effect in in-vitro models of Parkinson's Disease that is superior to each of the compounds individually. This preliminary data should be replicated and confirmed in other preclinical models of Parkinson's Disease and ultimately in clinical trials."

Combination therapy • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • NEFH

TZ-DLB: Terazosin for Dementia with Lewy Bodies (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Qiang Zhang | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2028

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease

Network Analysis and Machine Learning for Signal Detection and Prioritization Using Electronic Healthcare Records and Administrative Databases: A Proof of Concept in Drug-Induced Acute Myocardial Infarction. (PubMed, Drug Saf) - "Overall, our novel method demonstrates that network analysis is a valuable tool for signal detection and prioritization in drug-induced AEs based on EHRs and administrative databases."

Journal • Cardiovascular • Myocardial Infarction

Target Engagement of Terazosin in Healthy Adults (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: University of Iowa | Trial completion date: Jun 2024 ➔ Jun 2025

Trial completion date

Drug Development. (PubMed, Alzheimers Dement) - "Overall, this study will decipher the potential of TZ to treat AD and present new molecular candidates that can be targeted to cure or delay the progression of AD."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • PGK1

Separate and combined blockades of α- and β-adrenergic receptors in forearm sweating induced by adrenergic agents and exercise in the heat in young adults. (PubMed, Am J Physiol Regul Integr Comp Physiol) - "Adrenergic receptor blockade was induced via the separate and combined iontophoretic administration of terazosin (α-adrenergic receptor antagonist) and propranolol (β-adrenergic receptor antagonist) on forearm skin. Further, α- but not β-adrenergic receptors independently modulate the regulation of forearm sweating during exercise in the heat. Finally, the bretylium-induced reduction in forearm sweat rate during exercise likely occurs independently of α- and β-adrenergic receptors."

Journal

Xuanju Compound Capsule VS Terazosin in treatment of chronic prostatitis: a Prospective Randomized Controlled Trial (ANZCTR) - P3 | N=1000 | Withdrawn | Sponsor: zhou tie | Not yet recruiting ➔ Withdrawn

Trial withdrawal • CD4 • CXCL8 • IL2 • TNFA

Activation of glycolysis alleviates mitochondrial impairments caused by social isolation in Drosophila. (PubMed, Biochem Biophys Res Commun) - "Additionally, terazosin, an alpha-1 adrenergic receptor antagonist known to activate Pgk, produced a similar rescue effect. Our study elucidates a key principle of SI-induced psychological damage and proposes a drug targeting strategy for future validation."

Journal • Metabolic Disorders • ADRA1B

Exploring increased phosphoglycerate kinase 1 (PGK1) activity as a potential therapeutic target in MND (ALS-MND 2024) - "HEK-293 cells were transfected with a plasmid vector encoding human PGK1. PGK1 overexpression was confirmed 48 hours after transfection with western blot which showed a greater than 3-fold increase in PGK1 expression compared to control cells. Using an optimised PGK1 activity metabolic assay (2), we confirmed that the overexpressed PGK1 was functional with an increase in PGK1 activity 2.5x that of controls."

PGK1

Circadian chronotherapies of coronary heart disease and its biological risk factors: A United States Prescribers' Digital Reference-based review. (PubMed, Chronobiol Int) - "For arterial hypertension, dosing of terazosin and guanfacine is recommended in the evening and thiazide, thiazide-like, and sulfonamide diuretics morning; Verapamil (Verelan®) morning, its "PM" formulation evening, and long-acting diltiazem (Cardizem® LA), per clinical goal, morning or evening...For tobacco dependence, transdermal nicotine patch application is recommended in the morning, and bupropion early, but not late, during the wake span. For alcohol dependence, disulfiram is intended for morning ingestion. For thromboembolism prophylaxis, factor Xa inhibitor rivaroxaban is recommended at dinner and low-dose acetylsalicylic acid before bedtime. Medications for angina pectoris and edema of congestive heart failure are stipulated for morning administration. Overall, >200 medications prescribed to manage CHD and its risk factors qualify as chronotherapies."

Journal • Review • Addiction (Opioid and Alcohol) • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hypertension • Nicotine Addiction • Obesity • Pulmonary Arterial Hypertension • Tobacco Addiction

Enhanced lung endothelial glycolysis is implicated in the development of severe pulmonary hypertension in type 2 diabetes. (PubMed, Am J Physiol Lung Cell Mol Physiol) - "Augmentation of glycolysis by terazosin exacerbated hypoxia-induced PH in CH mice but not in DH mice. On the contrary, inhibiting GAPDH (a key enzyme of the glycolytic pathway) by koningic acid ameliorated hypoxia-induced PH in DH mice but had no effect in CH mice. These data suggest that enhanced glycolysis in diabetic mice is involved in severe hypoxia-induced PH, and glycolysis inhibition is a potential target to reduce the severe progression of PH in diabetic patients."

Journal • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Type 2 Diabetes Mellitus • GAPDH

Terazosin, a repurposed GPR119 agonist, ameliorates mitophagy and β-cell function in NAFPD by inhibiting MST1-Foxo3a signalling pathway. (PubMed, Cell Prolif) - "Terazosin activates GPR119 on the surface of pancreatic β-cells, enhancing mitophagy and alleviating β-cell dysfunction in the context of NAFPD by suppressing the MST1-Foxo3a signalling pathway. Terazosin could be considered a priority treatment for patients with concomitant NAFPD and hypertension."

Journal • Cardiovascular • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Hypertension • Obesity • Pancreatitis • MST1